Pre-Surgery drug cocktail aims to wipe out rectal cancer

NCT ID NCT01871571

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This trial investigates whether giving a combination of bevacizumab (a drug that blocks blood vessel growth to tumors) and chemotherapy before surgery can eliminate all signs of cancer in people with stage II or III rectal cancer. Participants receive the treatment before their planned surgery, and researchers check if the cancer is completely gone in the removed tissue. The goal is to see if this approach leads to better long-term outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
bevacizumab (Avastin) plus chemotherapy (fluorouracil, leucovorin calcium, oxaliplatin)
What this could lead to
If successful, this approach could become a standard treatment to shrink rectal tumors before surgery, potentially improving survival and reducing recurrence.
What could go wrong
This is a small phase II trial, so results may not apply to all patients. Side effects from chemotherapy and bevacizumab can be serious, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUCINOUS ADENOCARCINOMA OF THE RECTUM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.